AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Analysts Cut Inspire Medical's Price Target Ahead of Q1 Earnings Report
ByAinvest
Monday, Jul 14, 2025 12:37 pm ET1min read
Leerink analysts have revised Inspire Medical's (INSP) target price from $176 to $149, maintaining a Market Perform rating. The adjustment reflects recent financial disclosures and valuation insights. The average target price from 16 analysts is $216.68, indicating a 66.34% upside from the current price. Inspire Medical reported a 23% increase in revenue for Q1 2025 and provided full-year 2025 revenue guidance of $940 million to $955 million, representing 17% to 19% growth year-over-year.
Leerink analysts have revised their target price for Inspire Medical Systems Inc (INSP) from $176 to $149, while maintaining a Market Perform rating. This adjustment comes in anticipation of the company's upcoming quarterly earnings release. The update aligns with recent financial disclosures and new perspectives on valuation premiums within the industry.The average target price from 16 analysts is $216.68, indicating a 66.34% upside from the current price of $130.26. The consensus recommendation from 20 brokerage firms is currently 2.1, indicating an "Outperform" status. GuruFocus estimates the GF Value for INSP in one year to be $359.65, suggesting a 176.1% upside from the current price.
Inspire Medical reported a 23% increase in revenue for Q1 2025, reaching $201.3 million. The company also provided full-year 2025 revenue guidance of $940 million to $955 million, representing 17% to 19% growth year-over-year. The full-year diluted net income guidance was raised to a range of $2.20 to $2.30 per share, reflecting confidence in future profitability.
However, the second quarter of 2025 is expected to be a transition period due to the launch of the Inspire V system, which may impact revenue growth. Revenue outside the US decreased by 6% year-over-year, indicating challenges in international markets. The company anticipates some inventory destocking and patient warehousing for the Inspire V system, which could affect short-term financial performance.
The revised target price and earnings expectations reflect a balanced view of Inspire Medical's performance and potential. Investors should closely monitor the company's earnings report for further insights.
References:
[1] https://www.gurufocus.com/news/2974954/inspire-medical-insp-target-price-cut-ahead-of-earnings-report-insp-stock-news
[2] https://www.tipranks.com/stocks/fold/forecast
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet